IAP6 Rec'd PCT/PTO 2.1 FEB 2006 for PTO/SB/21 (09-04)*Transmittal Fo

Status Letter

Identify below):

Other Enclosure(s) (please

	u	# O : tot	,	App	proved for use through 07/31/2006. OMB 0651-0031 nark Office; U.S. DEPARTMENT OF COMMERCE
	E			Application Number	10/554185
\o,	TRANSMITTA	L		Filing Date	October 21, 2005
				First Named Inventor	Mark T. Bilodeau
FEB	[61 - 8]			Art Unit	To be determined
PATROFFE	be used for all correspondence after initial			Examiner Name	To be determined
1	Total Number of Pages in This Submission	n	-	Attorney Docket Number	21377YP
		ENCL	(Check all that appl	y)	
	Fee Transmittal Form	Fee Transmittal Form			After Allowance Communication to Technology Center (TC)
	After Final Affidavits/declaration(s) Petitic Provis		☐ Licensing-related Papers ☐ Petition		Appeal Communication to Board of Appeals and Interferences
			ion to Con isional Ap		Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
				ney, Revocation	Proprietary Information

Terminal Disclaimer

CD, Number of CD(s)

Request for Refund

- 16 references attached

Remarks

Extension of Time Request

Express Abandonment Request

Certified Copy of Priority

Response to Missing Parts/

Incomplete Application

Document(s)

اد

Information Disclosure Statement

Res	ponse to Missing Parts er 37 CFR 1.52 or 1.53			
	SIGNAT	RE OF APPLICANT, ATTO	ORNEY, OR AGENT	
Name	Matthew A. Leff	Registrat	ion No. (Attorney/Agent)	50,149
Signature	The C	1//	Date	2/15/2006

E UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Mark 1. Bilodeau, et al.

Serial No. 10/554,185

Filed: October 21, 2005

For: INHIBITORS OF AKT ACTIVITY

Art Unit:	To be determined

Examiner: To be determined

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- 3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
- 4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By Stephonie Ricards Date 2-15-00

RELATED APPLICATION

INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

U. S. SERIAL NUMBER	FILING DATE	MERCK CASE					
If this is inconvenient, additional copies will be submitted upon reques	t.						
6. In accordance with 37 C.F.R. 1.97, (check one)							
the attached information is filed within three months of the filing da	ate of the captioned case.						
the attached information is filed more than three months after the Office Action on the merits.	the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.						
the attached information is filed before the mailing of a first Office examination under §1.114.	the attached information is filed before the mailing of a first Office action after the filing of a request for continued examination under §1.114.						
Office Action on the merits, but before the mailing date of a Final A	the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action, Notice of Allowance, or an action that otherwise closes prosecution in the application. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).						
each item of information contained in this Information Disclosure S from a foreign patent office in a counterpart foreign application no Statement.							
each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the information disclosure statement.							
no item of information contained in this Information Disclosure State foreign patent office in a counterpart foreign application, and, to the after making reasonable inquiry, was known to any individual desiments prior to the filing of this Statement.	e knowledge of the person	signing the certification					
	Respectfully submitted,						

By: Matthew A. Leff // For Applicant(s)

Reg. No. 50,149

MERCK & CO., INC. Patent Dept., RY60-30

P.O. Box 2000

(732)594-<u>1404</u>

Rahway, N.J. 07065-0907

Date: February 15, 2006

						Patent and Tradement Office; U.S DEPARTMENT OF COMMERCE
4	Subs	stitute for form 1449A/PTO				COMPLETE IF KNOWN
	IN	FORMATION I	DIS	CLOSURE	Application Number	10/554,185
NP	E	CATENAENIT DX	A TO	DI ICANT	Filing Date	October 21, 2005
[/]	4STATEMENT BY APPLICANT				First Named Inventor	Mark T. Bilodeau
FEB 2	J 5008 F				Group Art Unit	To be determined
		(use as many sheets	as n	necessary)	Examiner Name	To be determined
TRACE IN	PS Heet	1	of	3	Attorney Docket Number	21377YP
						`

			U.S. PA	TENT DOCUMENTS	
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		2005/0222155		Bilodeau, et al.	10/06/2005
		2002/0127214		Hemmings	09/12/2002
		2005/0288294		Duggan, et al.	12/29/2005
		2004/0102360		Barnett, et al.	05/27/2004
		2005/0130977		Lindsley, et al.	06/16/2005
		6,060,491		Pruitt, et al.	05/09/2000
		2004/0106540		Barnett, et al.	06/03/2004
		2004/0116433		Owens, et al.	06/17/2004
		2004/0122012		Owens, et al.	06/24/2004
		6,960,584		Carling, et al.	11/01/2005
		2005/0159422		Lindsley, et al.	07/21/2005
		2005/0182256		Duggan, et al.	08/18/2005
-					
			-		
				· · · · · · · · · · · · · · · · · · ·	

	FOREIGN PATENT DOCUMENTS							
Examiner	Cite	Foreign Patent Document Kind			Name of Patentee or Applicant	Date of Publication of		
Initials*	No.	Office	Number /	Code (if known)	of Cited Document	Cited Document MM-DD-YYYY		
		PCT	WO 97/08167 /		Smithkline Beecham Plc	03/06/1997		
		PCT	WO 96/11929 √		Smithkline Beecham Plc.	04/25/1996		
		PCT	WO 01/66525 🗸		Astrazeneca Ab.	09/13/2001		
		PCT	WO 97/49704 ✓		Janssen Pharmaceutica Nv.	12/31/1997		
		PCT	WO 97/22360 ✓		Medical Research Counsil	06/26/1997		
		PCT	WO 01/91754 /		Peptor Ltd.	12/06/2001		
		PCT	WO 96/23769 /		Smithkline Beecham PLC.	08/08/1996		
		PCT	WO 02/083138 ¹		Merck & Co., Inc.	10/24/2002		
		PCT	WO 03/084473 /		Merck & Co., Inc.	10/16/2003		
		PCT	WO 94/10171		Pfizer Inc.	05/11/1994		

Examiner Signature	Date Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

					Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE		
Su	bstitute for form 1449A/PTO			COMPLETE IF KNOWN			
I	NFORMATION	DIS	CLOSURE	Application Number	10/554,185		
C	TATENTENIT DA	A D	DI ICANIT	Filing Date	October 21, 2005		
3	TATEMENT BY	AP	PLICANI	First Named Inventor	Mark T. Bilodeau		
			,	Group Art Unit	To be determined		
	(use as many sheets	as n	ecessary)	Examiner Name	To be determined		
Sheet	2	of	3	Attorney Docket Number	21377YP		

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY		
· ·			_				

				· · · · · · · · · · · · · · · · · · ·			

	FOREIGN PATENT DOCUMENTS								
			Foreign Patent Document			Date of Publication of			
Examiner Initials*	Cite No.	Office	e Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY			
		PCT	WO 96/23783 ✓		Smithkline Beecham Plc.	08/08/1996			
		PCT	WO 04/024728 /		Glaxo Group Limited	03/25/2005			

Examiner Signature	 Date Considered	
		

	Substitute for form 1449B/PTO		COMPLETE IF KNOWN		
INFORMATION DISCLOSURE				Application Number	10/554,185
STATEMENT BY APPLICANT			DI ICANE	Filing Date	October 21, 2005
			PLICANI	First Named Inventor	Mark T. Bilodeau
				Group Art Unit	To be determined
	(use as many sheets	as n	ecessary)	Examiner Name	To be determined
Sheet	3	of	3	Attorney Docket Number	21377YP

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.						
	√.	Kunick, et al. Database Caplus on Stn, J. Medicinal Chemistry, Vol. 47(1), pp. 22-36, Abstract, 2004					
		Barnett, et al. Database Calpus on Stn., Bioorganic & Medicinal Chemistry, Vol. 26(11), pp. 1221-1226, Abstract, 2004					
	J	DeFeo-Jones, et al. Molecular Cancer Therapeutics, Vol. 4(2), pg. 271-279 (2005)					
	-	Lindsley, et al. Bioorganic & Medicinal Chemistry Letters, Vol. 15(3), pg. 761-764 (2005)					
1-							
	-						

Examiner Signature	Date Considered	
0.8	00110100100	